Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryDec072019	Fate Therapeutics Announces Clinical Data from Landmark Phase 1 Studies of First-ever Universal, Off-the-shelf, iPSC-derived NK Cell Cancer Immunotherapy Programs No Morphologic Evidence of Leukemia and Complete Neutrophil Recovery Observed in First Patient Treated with FT516 Monotherapy for AML following First Dosing Cycle No Dose-limiting Toxicities or FT500-related SAEs Reported in First 12 Patients Treated with FT500 for Advanced Solid Tumors Favorable Read All »	View HTML
Toggle SummaryDec102022	Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derived CAR T-cell Therapy at 2022 ASH Annual Meeting FT819 Off-the-Shelf CAR T-cell Product Candidate Derived from Clonal Engineered Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus Interim Phase 1 Dose-escalation Data Indicate Favorable Safety Profile with Complete Responses in Heavily Pre-treated Patients with Aggressive Read All »	View HTML
Toggle SummaryOct042013	Fate Therapeutics Announces Closing of Initial Public Offering and Exercise of Option to Purchase Additional Shares SAN DIEGO, Oct. 4, 2013 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced the closing of its previously announced initial public offering of Read All »	View HTML Fate Therapeutics Announces Closing of Initial Public Offering and Exercise of Option to Purchase Additional Shares 11.1 KB
Toggle SummaryOct142010	Fate Therapeutics Announces Collaboration with BD to Develop and Commercialize Induced Pluripotent Stem Cell Technology San Diego, CA and Ottawa, Canada (October 14, 2010) – Fate Therapeutics, Inc. has forged a collaboration and license agreement with BD (Becton, Dickinson and Company), a leading global medical technology company, through its BD Biosciences segment, for the joint development and worldwide Read All »	View HTML Fate Therapeutics Announces Collaboration with BD to Develop and Commercialize Induced Pluripotent Stem Cell Technology 12.6 KB
Toggle SummaryMay272015	Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares SAN DIEGO , May 27, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced the closing of an underwritten public offering of Read All »	View HTML Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 147.1 KB
Toggle SummaryDec152017	Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares SAN DIEGO, Dec. 15, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the closing of an underwritten public offering of Read All »	View HTML Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 378.4 KB
Toggle SummarySep182019	Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares SAN DIEGO , Sept. 18, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “ Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the closing Read All »	View HTML
Toggle SummaryJun112020	Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares SAN DIEGO , June 11, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “ Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the closing Read All »	View HTML
Toggle SummarySep252018	Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares SAN DIEGO , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the closing of an underwritten public offering of Read All »	View HTML
Toggle SummaryJan082021	Fate Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants, and Full Exercise of Underwriters’ Option to Purchase Additional Shares SAN DIEGO , Jan. 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “ Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the closing Read All »	View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.